Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Generalized Pustular Psoriasis

In brief

This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).

Key facts

Study ID
NCT05366855
Run by
Vanda Pharmaceuticals
People needed
42
Starts
2022-04-21
Expected to finish
2024-07-12
Last updated by the study team
2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.